GlassScriptPhysician profile
Stephen Hsieh
NPI 1982664678
$16,821.02
in general payments reported to CMS, 2019-2025
68 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,762 · 2020: $2,001 · 2021: $3,584 · 2022: $2,883 · 2023: $2,125 · 2024: $1,832 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,518 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,517.65 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,724.03 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,489.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,313.02 | 2021-2025 | |
| Pfizer INC. | $1,260.47 | 2019-2025 | |
| Lilly USA, LLC | $1,193.51 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $825.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $778.16 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Otsuka America Pharmaceutical, INC. | $677.55 | 2020-2025 | Rexulti, Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $584.15 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $500.94 | 2019-2023 | Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $483.41 | 2020-2021 | |
| Amgen INC. | $447.12 | 2019-2025 | Otezla, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $391.64 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $372.85 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $359.05 | 2019-2024 | Dificid |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hsieh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.